Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine

National Institute of Allergy and Infectious Diseases (NIAID)

Status and phase: Completed; Phase 1

Conditions: Mosquito-Borne Infectious Diseases

Treatments: Biological: Alhydrogel® Adjuvant; Biological: Montanide ISA-51 Adjuvant; Biological: Saline Placebo; Biological: AGS-v PLUS Vaccine

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT04009824

AGS-v PLUS

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and immunogenicity of AGS-v PLUS, a universal mosquito-borne disease and mosquito control vaccine, in healthy volunteers.

Full description

This study will evaluate the safety and immunogenicity of AGS-v PLUS, a universal mosquito-borne disease and mosquito control vaccine, in healthy volunteers.

Participants will be randomly assigned to five groups.

Participants in Group 1 will receive placebo on Days 1 and 22.

Participants in Group 2 will receive unadjuvanted AGS-v PLUS vaccine on Days 1 and 22.

Participants in Group 3 will receive Montanide ISA-51 adjuvanted AGS-v PLUS vaccine on Day 1 and placebo on Day 22.

Participants in Group 4 will receive Montanide ISA-51 adjuvanted AGS-v PLUS vaccine on Days 1 and 22.

Participants in Group 5 will receive Alhydrogel® adjuvanted AGS-v PLUS vaccine on Days 1 and 22.

Participants will be in the study for approximately 12 months. During this time, they will attend several study visits, which may include physical examinations, blood collection, skin biopsies, and a mosquito feeding procedure. Study staff will also follow up with participants by phone several times throughout the study.

Enrollment: 51 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy women and men who are greater than or equal to 18 and less than or equal to 50 years of age.

• Willingness to complete all study visits and comply with all study requirements.

• A male participant is eligible for the study if he agrees to practicing abstinence or using a condom with spermicide plus an acceptable form of contraception (see inclusion criteria below) being used by any female partner from 4 weeks before study start to 12 weeks after the second vaccine administration.

• A female participant is eligible for this study if she is not pregnant or breast feeding and 1 of the following:

  • Of non-child bearing potential (i.e., women who have had a hysterectomy or tubal ligation, or are postmenopausal, as defined by no menses in greater than or equal to 1 year).
  • Of childbearing potential but agrees to practice effective contraception or abstinence for 4 weeks before study initiation and 12 weeks after the second vaccine administration. Acceptable methods of contraception include a female partner who is the sole sexual partner of the female participant, a male partner who is sterile and is the sole sexual partner of the female participant, or a male partner who uses a condom with spermicide plus 1 or more of the following: 1) implants of levonorgestrel; 2) injectable progestogen; 3) an intrauterine device with a documented failure rate of less than 1%; 4) oral contraceptives; and 5) double barrier method including diaphragm.

• Willing to have samples stored for future research.

• Agrees to abstain from alcohol intake for 24 hours before each study visit.

• Agrees to not donate blood or blood products throughout the study.

• Score greater than or equal to 70% on comprehension quiz at screening

Exclusion criteria

• Participant has any underlying or current medical condition, which, in the opinion of the Investigator, would interfere with the participation in the study.
• Individual with body mass index (BMI) less than or equal to 18 and greater than or equal to 40.
• Participants who have a clinically significant (as determined by the PI or designee) baseline Grade 1 or greater toxicity, or any Grade 2 or greater toxicity (regardless of clinical significance) by the toxicity table.
• Receipt of blood or blood products including immunoglobulin within 3 months before enrollment.
• Receipt of any unlicensed drug within 3 months or 5.5 half-lives (whichever is greater) before enrollment.
• Receipt of any unlicensed vaccine within 6 months before enrollment.
• Participated in study NCT03055000 testing safety and immunogenicity of AGS-v.
• Self-reported or known history of alcoholism or drug abuse within 6 months before enrollment.
• Self-reported or known history of psychiatric or psychological issues that require treatment and are deemed by the PI or designee to be a contraindication to protocol participation.
• History of a previous severe allergic reaction with generalized urticaria, angioedema, anaphylaxis or anaphylactoid reaction.
• Any condition or event that, in the judgment of the PI or designee, is a contraindication to protocol participation or impairs the volunteer's ability to give informed consent.
• Known allergy to any vaccine component, including adjuvants.
• History of severe immunization reaction.
• Severe allergic reaction to mosquito bites (anaphylaxis)
• Have taken oral or parenteral (including intra-articular) corticosteroids of any dose within 30 days before study vaccination
• Have taken high-dose inhaled corticosteroids* within 30 days before each study vaccination (* High-dose defined per age as using inhaled high dose per reference chart: https://www.nhlbi.nih.gov/sites/default/files/media/docs/asthma_qrg_0_0.pdf)
• Received or plan to receive a licensed, live vaccine within 30 days before or after the study vaccination
• Received or plan to receive a licensed, inactivated vaccine within 14 days before or after study vaccination
• Serologic evidence of infection with HIV, hepatitis B virus, or hepatitis C virus
• Ongoing chronic skin condition, or acute skin condition at the time of vaccination or mosquito feeding, except for mild eczema.
• History of keloid formation after previous biopsies, lacerations, abrasions, surgeries, or other skin procedures (e.g., cosmetic piercings) that are deemed by the PI or designee to be a contraindication to protocol participation.
• Pregnancy, breastfeeding, or planning to become pregnant up to one month after mosquito feeding.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

51 participants in 5 patient groups, including a placebo group

Group 1: Saline Placebo

Placebo Comparator group

Description:

Participants received placebo on days 1 and 22 by subcutaneous injection

Treatment:

Biological: Saline Placebo

Group 2: AGS-v PLUS Non-Adjuvanted

Experimental group

Description:

Participants received 1012 µg of unadjuvanted AGS-v PLUS vaccine on days 1 and 22 by subcutaneous injection

Treatment:

Biological: AGS-v PLUS Vaccine

Group 3: AGS-v PLUS + Adjuvant Montanide ISA-51 + Placebo

Experimental group

Description:

Participants received 1012 µg of AGS-v PLUS and Montanide ISA-51 on day 1 and placebo on day 22 by subcutaneous injection

Treatment:

Biological: Montanide ISA-51 Adjuvant

Biological: AGS-v PLUS Vaccine

Biological: Saline Placebo

Group 4: AGS-v PLUS + Montanide ISA-51

Experimental group

Description:

Participants received 1012 µg of AGS-v PLUS + Montanide ISA-51 on days 1 and 22 by subcutaneous injection

Treatment:

Biological: Montanide ISA-51 Adjuvant

Biological: AGS-v PLUS Vaccine

Group 5: AGS-v PLUS + Alhydrogel® Adjuvant

Experimental group

Description:

Participants received 1012 µg of AGS-v PLUS and Alhydrogel® on days 1 and 22 by subcutaneous injection

Treatment:

Biological: Alhydrogel® Adjuvant

Biological: AGS-v PLUS Vaccine